The Scandinavian leaders of AI in breast imaging presented their research at the ScreenPoint symposium at EUSOBI 2022 in Malmo, Sweden. Dr Kristina Lang presented the MASAI trial, the first prospective randomized controlled trial on the use of AI in breast screening as an alternative for double reading. Based on her previous retrospective studies, she is convinced that AI could lead to a more efficient and more effective screening programme. In the MASAI trial at Unilabs/Skane University Hospital Malmo, women are randomly assigned to a control arm where exams are double read as usual, or to the AI-based intervention arm: Transpara triages screening exams based on risk for malignancy and assigns 90% of all screening cases to single reading, and 10% to double reading. In addition, the top 1% most suspicious cases are automatically recalled.

Developer of AI systems for breast care ScreenPoint Medical BV announced the introduction of Transpara powered by FusionAI, an improved and enhanced version of Transpara 1.6, at the European Congress of Radiology virtual meeting in March. Transpara has been in use in more than 20 countries and ScreenPoint says that the latest clinical studies reveal major benefits for radiologists and patients: "Up to 35 per cent of examinations with interval cancers found on earlier mammograms and, to help reduce workload for increasingly pressured radiologists, up to 70 per cent of examinations can now be confidently labelled as normal. Overall Transpara has been shown to match the performance of specialist breast radiologists in both 2D and 3D studies." Transpara with FusionAI is up to 28 per cent more accurate than previous versions, helping to detect more cancers and earlier, the company added. See the full report on page 26 of the April 2021 issue of RAD Magazine.